Medical City Dallas Hospital Adopts Perimeter's Innovative OCT Imaging Technology for Surgery
Perimeter Medical Imaging AI (OTCQX:PYNKF) announced that Medical City Dallas Hospital, an 899-bed acute care facility, has adopted their S-Series OCT imaging technology for surgical procedures. This adoption follows the hospital's participation in a pivotal trial of Perimeter's next-generation B-Series device, which combines OCT with AI technology for breast-conserving surgeries.
The S-Series OCT technology, FDA-cleared in 2021, provides high-resolution visualization of tissue microstructures at the cellular level, offering superior imaging capabilities compared to traditional methods like X-ray, MRI, or ultrasound. The system is optimized to identify regions of interest in tissue microstructures down to 2mm, making it particularly effective for visualizing surgical margins.
Perimeter Medical Imaging AI (OTCQX:PYNKF) ha annunciato che il Medical City Dallas Hospital, una struttura di assistenza acuta con 899 posti letto, ha adottato la loro tecnologia di imaging S-Series OCT per le procedure chirurgiche. Questa adozione segue la partecipazione dell'ospedale a uno studio fondamentale sul dispositivo di nuova generazione B-Series di Perimeter, che combina OCT con tecnologia AI per interventi di conservazione del seno.
La tecnologia S-Series OCT, approvata dalla FDA nel 2021, offre una visualizzazione ad alta risoluzione delle microstrutture tissutali a livello cellulare, garantendo capacità di imaging superiori rispetto ai metodi tradizionali come radiografia, risonanza magnetica o ecografia. Il sistema è ottimizzato per identificare aree di interesse nelle microstrutture tissutali fino a 2 mm, risultando particolarmente efficace per visualizzare i margini chirurgici.
Perimeter Medical Imaging AI (OTCQX:PYNKF) anunció que el Medical City Dallas Hospital, una instalación de atención aguda con 899 camas, ha adoptado su tecnología de imagen S-Series OCT para procedimientos quirúrgicos. Esta adopción sigue a la participación del hospital en un ensayo clave del dispositivo de próxima generación B-Series de Perimeter, que combina OCT con tecnología de IA para cirugías conservadoras de mama.
La tecnología S-Series OCT, aprobada por la FDA en 2021, proporciona visualización de alta resolución de microestructuras tisulares a nivel celular, ofreciendo capacidades de imagen superiores a métodos tradicionales como rayos X, MRI o ultrasonido. El sistema está optimizado para identificar regiones de interés en microestructuras tisulares hasta de 2 mm, haciéndolo especialmente eficaz para visualizar los márgenes quirúrgicos.
Perimeter Medical Imaging AI (OTCQX:PYNKF)는 899병상 규모의 급성기 병원인 Medical City Dallas Hospital이 수술 절차에 자사의 S-Series OCT 영상 기술을 도입했다고 발표했습니다. 이 도입은 유방 보존 수술을 위해 OCT와 AI 기술을 결합한 차세대 B-Series 장치에 대한 병원의 중추적인 임상 시험 참여 이후 이루어졌습니다.
S-Series OCT 기술는 2021년에 FDA 승인을 받았으며, 세포 수준에서 조직 미세구조를 고해상도로 시각화하여 X선, MRI, 초음파 같은 전통적인 방법보다 우수한 영상 능력을 제공합니다. 이 시스템은 2mm 크기까지 조직 미세구조 내 관심 영역을 식별하도록 최적화되어 수술 경계 시각화에 특히 효과적입니다.
Perimeter Medical Imaging AI (OTCQX:PYNKF) a annoncé que le Medical City Dallas Hospital, un établissement de soins aigus de 899 lits, a adopté leur technologie d'imagerie OCT de la série S pour les interventions chirurgicales. Cette adoption fait suite à la participation de l'hôpital à un essai pivot du dispositif de nouvelle génération B-Series de Perimeter, qui combine l'OCT avec la technologie IA pour les chirurgies conservatrices du sein.
La technologie OCT de la série S, approuvée par la FDA en 2021, offre une visualisation haute résolution des microstructures tissulaires au niveau cellulaire, offrant des capacités d'imagerie supérieures aux méthodes traditionnelles telles que la radiographie, l'IRM ou l'échographie. Le système est optimisé pour identifier des zones d'intérêt dans les microstructures tissulaires jusqu'à 2 mm, ce qui le rend particulièrement efficace pour visualiser les marges chirurgicales.
Perimeter Medical Imaging AI (OTCQX:PYNKF) gab bekannt, dass das Medical City Dallas Hospital, eine Akutversorgungseinrichtung mit 899 Betten, ihre S-Series OCT-Bildgebungstechnologie für chirurgische Eingriffe übernommen hat. Diese Einführung folgt auf die Teilnahme des Krankenhauses an einer entscheidenden Studie des nächsten B-Series-Geräts von Perimeter, das OCT mit KI-Technologie für brusterhaltende Operationen kombiniert.
Die S-Series OCT-Technologie, die 2021 von der FDA zugelassen wurde, bietet hochauflösende Visualisierungen von Gewebemikrostrukturen auf zellulärer Ebene und übertrifft damit herkömmliche Methoden wie Röntgen, MRT oder Ultraschall. Das System ist darauf optimiert, Interessensbereiche in Gewebemikrostrukturen bis zu 2 mm zu erkennen, was es besonders effektiv für die Visualisierung chirurgischer Ränder macht.
- FDA-cleared S-Series OCT technology adoption by major 899-bed hospital
- Technology provides unique cellular-level visualization capabilities
- Ongoing clinical trial for next-generation B-Series device with AI integration
- Expanding nationwide deployment of S-Series OCT technology
- None.
Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries
"We are incredibly proud to partner with Medical City Dallas Hospital and its team of surgeons, who are truly innovators in their field," said Perimeter CEO Adrian Mendes. "Working with Dr. DiPasquale and Dr. Anderson and the Medical City Dallas team, who used our B-Series in the randomized controlled pivotal trial, has been invaluable to advancing our next-generation product and we are pleased that they are adopting our commercially approved S-Series to potentially enhance margin visualization in the OR."
Medical City Dallas Hospital is the latest
About Perimeter Medical Imaging AI, Inc.
Based in
S-Series OCT Intended Use and Unapproved Uses
The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, statements regarding the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; fees anticipated to be paid to the Agent and terms thereof; regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSXV, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Contacts
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Susan Thomas
Media Relations
Direct: 619-540-9195
Email: susan@endpointcommunications.net
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/medical-city-dallas-hospital-adopts-perimeters-innovative-oct-imaging-technology-for-surgery-302496263.html
SOURCE Perimeter Medical Imaging AI Inc.
FAQ
What is Perimeter Medical's (PYNKF) S-Series OCT technology used for?
When did the FDA clear Perimeter Medical's S-Series OCT technology?
How does Perimeter's OCT technology differ from traditional imaging methods?
What is Perimeter Medical's next-generation B-Series device?
Which hospital has recently adopted Perimeter Medical's OCT technology?
